Emerging studies suggest Retatru tide , a dual activator targeting both incretin and GIP , may offer a notable step forward for weight loss . Early human trials have indicated substantial losses in visceral tissue, conceivably outperforming existing weight-loss therapies . Nevertheless , more evaluation is required to thoroughly assess its sustaine